In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in